RxDoctor Payments Data

Jeffrey Buncher, MD

Family Medicine · Charleston, SCNPI 1255457693

Payments from drug & device makers

$21,362in general payments, 2019–2025

Across 149 payments — averaging $143.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$19K
  • AbbVie$515
  • Lilly USA, LLC$141
  • Alnylam Pharmaceuticals Inc.$122
  • Exact Sciences$115
  • Alkermes, Inc.$113
  • plus $1K from 28 others

What the payments were for

  • Speaking & faculty fees$5,87158%
  • Travel & lodging$1,26412%
  • Food & beverage$2,92429%
  • Education$691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,362 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$63,907
Medicare patients
95
Services billed
1,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$39,475
QuliptaAtogepant13$15,261
TrulicityDulaglutide15$14,332
FarxigaDapagliflozin Propanediol15$13,077
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl67$6,822
Gabapentin61$670
Ezetimibe12$542
Baclofen27$488
Amlodipine Besylate94$451
Atorvastatin Calcium68$425
Pregabalin23$423
Lisinopril49$389
Levothyroxine Sodium36$283
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$270
Oxycodone Hcl39$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$141$53,80752 claims
AbbVieQulipta$515$15,26113 claims
AstraZenecaFarxiga$76$13,07715 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$53$6,82267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →